arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Seres Therapeutics, Inc.

MCRB
$3.80 ▼ -0.22 (-5.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Seres Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $36.9M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -48.7%
FCF / Share $-2.31
Trailing P/E 8.1x
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$736.00K
↑ +105.6%
Net Income Profit after all expenses
$-19.91M
— 0.0%
Operating Margin Operating profit as % of sales
29.3%
↓ -25.1%
FCF / Share Free cash flow per share
$-2.31
↓ -35.1%
Long-Term Debt Long-term obligations
$110.00M
— 0.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
100
Returns
76
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters